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Letter to the Editor
Changes in hepatitis C virus antibody titer and viral
RNA load in non-Hodgkin’s lymphoma patients
after rituximab chemotherapy
Sir, We found that four of the 84 B-cell non-Hodgkin’s
lymphoma (NHL) patients treated with rituximab in our
institution from March 2004 to March 2007 were positive
for hepatitis C virus (HCV) antibody. We analyzed the
HCV-RNA and HCV antibody levels in these four patients
(two male and two female, with ages ranging from 43 to
80) and the characteristics of their cases are listed in
Table 1. Each patient had diffuse large B-cell type lym-
phoma (DLBL) and hepatitis C antibodies (HCV II, this
antibody was calculated IgG for HCV). The HCV-RNA
load in each patient was measured (in the same labora-
tory) by using the polymerase chain reaction (PCR) in a
method described elsewhere (Takeuchi et al., 1999). Their
HCV-RNA loads ranged from 20 to 2100 KIU/ml (more
than 5 KIU/ml was positive; max 5000 KIU/ml) in all
patients. All cases received rituximab (375 mg/m
2 on day
1) plus CHOP or a CHOP-like regimen (cyclophospha-
mide 750 mg/m
2 on day 2, vincristine 1.4 mg/m
2 on day
2, doxorubicin 50 mg/m
2 on day 2, and with/without
prednisolone 60 mg/day from day 2 to day 6) or a THP-
CO (cyclophosphamide 500 mg/m
2 on day 2, vincristine
1.0 mg/m
2 on day 2, pirarubicin 30 mg/m
2 from day 2 to
day 6) regimen at 3-week intervals. One patient received
40-Gy radiotherapy to the bulky residual mass remaining
after chemotherapy. They received three to six courses of
these regimens (Figure 1). Three patients (cases 2 and 3)
obtained a complete response (CR) and one (case 1)
obtained an unconﬁrmed complete response (CRu). The
case-4 patient relapsed three years after chemotherapy,
but each of the others kept a CR or CRu from one to four
years after chemotherapy. The HCV antibodies in all four
patients decreased slightly throughout the clinical course.
The HCV-RNA load in case 1 was not elevated after the
administration of chemotherapy without rituximab
(CHOP) but was elevated after the administration of
R-CHO (CHOP without predonisolone) and was
decreased after the administration of CHO (without ritux-
imab). In this case, the HCV-RNA load was elevated only
after the administration of rituximab. In the other cases,
the HCV-RNA load also increased gradually elevated after
the administration of R-CHO or R-THP-CO (THP-COP
without predonisolone). In case 3, the HCV-RNA load
increased gradually elevated after the administration of
R-CHO and decreased after the administration of CHO.
The HCV-RNA load was elevated after the administration
of rituximab or a rituximab-containing regimen and was
decreased after the treatment without rituximab.
We previously reported changes in the titers of
antibodies to HBsAg (anti-HBs) and to hepatitis B core
antigen (anti-HBc) that were due to treatment with
chemotherapy and rituximab (Tsutsumi et al., 2005).
Here, we investigated our HCV-RNA-positive NHL
patients after the administration of rituximab and CHO
or CHOP. All of these cases showed elevated HCV-RNA
load after the administration of chemotherapy and ritux-
imab but showed decreased HCV-RNA load after chemo-
therapy without rituximab. The HCV-RNA load in case 1
was elevated after the administration of rituximab alone,
suggesting that rituximab elevated the HCV viral load.
These results suggest that the immune system against
HCV may function differently from that against hepatitis
B virus.
Some reports showed a correlation between HCV and
B-cell type NHL (Mele et al., 2003; de Sanjose et al.,
2004; Takeshita et al., 2006). But in these cases, HCV-
RNA was not positive for the lymph node specimen
involved in the lymphoma. HCV-RNA and the develop-
ment of NHL were discussed in many cases.
HCV-RNA load elevation after the administration of
rituximab and CHOP has been reported by only two
groups of investigators (Aksoy et al., 2006; Lake-Bakaar
et al., 2007). In those cases, the reactivation of HCV was
shown after chemotherapy and rituximab treatment.
Lake-Bakaar et al. (2007) considered how B-cell deple-
tion affected the reduction of neutralizing IgM for HCV.
They reported that anti-E1/E2 HCV antibodies were not
affected by B-cell depletion, but we found HCV antibod-
ies to be decreased. The HCV antibody we examined was
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Figure 1. Time course of HCV-RNA load and HCV-antibody titer. (a) HCV-RNA load was elevated after treatment
with rituximab or a chemotherapy regimen containing rituximab. (b) HCV-RNA load was elevated and HCV-anti-
body titer was decreased after rituximab and CHO. (c) HCV-RNA load was elevated after rituximab-containing regi-
men and decreased after chemotherapy without rituximab. HCV-antibody titer was decreased after rituximab-
containing regimen. (d) HCV-RNA load was elevated after rituximab-containing regimen.
Table 1. HCV antibody or HCV-RNA status of the patients with administration of rituximab
Cases
Age/
gender Disease
HCV-II
(before/
after)
Anti HCV-II titer
with rutuximab
treatment
(before/after)
HCV-RNA
with rutuximab
treatment
(before/after)
Ch E
(before/
after)
Maximum
AST/ALT
during
treatment
Number of
rituximab
treatments Outcome
Case 1 55/M DLBCL IV +/+ 55.4/28.7 20/5000 141/156 295/230 4 Alive
Case 2 43/F DLBCL III +/+ 73/60.6 2220/5000< 301/281 65/62 6 Alive
Case 3 74/M DLBCL IV +/+ 98.2/59.9 62/924 178/116 171/124 3 Alive
Case 4 80/F DLBCL IV +/+ +/+ 304/657 101/123 101/123 3 Alive
HCV, hepatitis C virus; DLBCL, diffuse large B-cell lymphoma; CS, clinical stage; Ch E, cholinesterase; AST, aspartate
aminotransferase; ALT, alanine aminotransferase.
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LETTER TO THE EDITOR 469IgG, and the difference between our results and those
reported previously suggests that the IgM response for
HCV might not be paralleled by the IgG response.
Although B-cell depletion continued for several months,
the HCV viral load did not remain elevated, suggesting
that the B-cell depletion was not the only reason for the
elevated HCV viral load. The number of regulatory T
cells, on the other hand, was elevated 30 days after
administration of rituximab and decreased within
90 days (Vigna-Perez et al., 2006). The decreased popula-
tion of T cells may have been too small to suppress the
HCV viral load. Although aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) levels were
elevated in all cases, cholinesterase was decreased in
only one. This may show that HCV-RNA load elevation
was not the problem of standard chemotherapy and
rituximab treatment for lymphoma patients. But in fol-
licular lymphoma, maintenance therapy of the perio-
dical administration of rituximab may lead to the
continuous elevation of the HCV-RNA load and con-
sequently may induce liver cirrhosis. We found that
rituximab leads to elevated HCV viral load during the
clinical course of lymphoma. Periodic administration of
rituximab for an extended period of time may lead to
the continuous elevation of HCV-RNA load and com-
promise the liver function of HCV-positive lymphoma
patients.
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